Business Development & Finance Committee

Charter

The Business Development & Finance Committee (BDF) strives to:

• Address the evolving CGT business model and key considerations including clinical development, partnerships, financing, and commercialization.
  
  

Projects & Objectives

• The BDF champions the ISCT Investigators to Investors (I to I) program, which strives to bridge the knowledge gap between investigators and investors within the cell and gene therapy (CGT) sector. 
• Conducts bi-annual surveys with aim to understand investor perceptions of key opportunities and challenges in the CGT field at the time.
• Curates topical educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing for both the investor and investigator profiles
• Develops roundtables for ISCT Annual and Regional meetings on topics related to Investment & Partnering Strategies
  
  

Ideal Member Profile

• Business development executives (e.g., CEOs, SVPs/VPs, etc.)
• Cell and Gene Therapy investors & analysts, by invitation
  
  

Selected Publications

• Cell and Gene Therapy Investment: Evolution and Future Outlook on Investor Perspectives (2024)
• Investor Perspective of Cell & Gene Therapy: A 2018 Snapshot (2021)
  
  

The Committee

Co-Chair

Sven Kili, MBChB, MRCS (Eng)

Sven Kili Consulting
Saisei Ventures
CCRM
United Kingdom

Co-Chair

Patrick Rivers, MBA

aMoon Fund
United States

Members:

Sophie Bardy
BioBridge Global

Ksenia Bezverbnaya
CCRM

Ann Brady
Avectas

Daniela Buchmayr
Sarcura GMBh

Dan Catron
CTMC

Pascale Charbonnel
SCTbio

Matthieu Coutet
Sofinnova Partners

Romain de Rauville
ExoXpert

Chathuranga de Silva
BioCentriq

Mark Flower
Cryoport Systems

Miguel Forte
mC4Tx

Jules Foster
Lonza

Ingrid Gafanhão
Redwheel

Sam Goldsmith
Cell and Gene Therapy Catapult

Asthika Goonewardene
Truist Securities

Madhup Khotari
Vitalant

Mathias Kroll
Cynata

Traci Kyes
ViroCell Biologics

Belinda Le
BD Biosciences

Adam McPherson
OriGen Biomedical

Marie-Laure Muiras
bioMérieux

Lise Munsie
CCR

Eck Redmond
NMDP

Antonio Scatena
Gateway Analytical

Nathan Smith
Cell Therapies Pty Ltd

John So
FUJIFILM Irvine Scientific

Jennifer Solomon
STEMCELL Technologies

Mathias Svahn
NextCell Pharma AB

Steven Thompson
BioLife Solutions, Inc.

Franziska Uber
PL BioScience

Geoff Uhl
Terumo Blood and Cell Technologies

Phil Vanek
Gamma Biosciences

Jonathan Yeh
Saisei Ventures

Victoria Zellmer
MaxCyte

Julia Zhen
Thermo Fisher Scientific

Sanjin Zvonić
Dark Horse Consulting Group